GLPwatch

Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy.

Nat Commun · 2017

Last updated 2026-05-28

Researchers developed a skin patch with tiny needles that delivers a diabetes drug called exendin-4 (Ex4) in a smarter way. The patch contains two types of mineral-coated particles—one releases Ex4 when blood sugar is high, while the other holds an enzyme that helps control the release. In tests, this system improved blood sugar control and allowed the drug to be delivered painlessly through the skin for long-term use.

AI summary of the abstract below.

JournalNat Commun, 2017
Citations137
Relative citation ratio5.78
NIH percentile94
Molecules
Conditions studied Type 2 Diabetes

Abstract

The delivery of therapeutic peptides for diabetes therapy is compromised by short half-lives of drugs with the consequent need for multiple daily injections that reduce patient compliance and increase treatment cost. In this study, we demonstrate a smart exendin-4 (Ex4) delivery device based on microneedle (MN)-array patches integrated with dual mineralized particles separately containing Ex4 and glucose oxidase (GOx). The dual mineralized particle-based system can specifically release Ex4 while immobilizing GOx as a result of the differential response to the microenvironment induced by biological stimuli. In this manner, the system enables glucose-responsive and closed-loop release to significantly improve Ex4 therapeutic performance. Moreover, integration of mineralized particles can enhance the mechanical strength of alginate-based MN by crosslinking to facilitate skin penetration, thus supporting painless and non-invasive transdermal administration. We believe this smart glucose-responsive Ex4 delivery holds great promise for type 2 diabetes therapy by providing safe, long-term, and on-demand Ex4 therapy.

Verbatim abstract via PubMed 29176623 ↗